Safety and Efficacy Study for Reverse Flow Used During Carotid Artery Stenting Procedure



Status:Active, not recruiting
Conditions:Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:November 2012
End Date:June 2016

Use our guide to learn which trials are right for you!

INVESTIGATION of FLOW ALTERED, SHORT TRANSCERVICAL CAROTID ARTERY STENTING in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE With Filter.

The purpose of this study is to evaluate the safety and effectiveness of the MICHI™
Neuroprotection System with Filter (MICHI™ NPS+f) in providing cerebral embolic protection
during carotid artery stenting. It will be used in conjunction with a FDA approved carotid
artery stent for the treatment of carotid artery disease.

Cerebral embolization during carotid artery stenting (CAS) can often precipitate severe
adverse neurological effects. Most major clinical studies of CAS have used distal filters
for cerebral protection and have compared the neurologic complication rates with those of
carotid endarterectomy (CEA). Many currently available embolic protection devices, however,
have limited efficacy in capturing microembolic debris that is liberated during stenting,
pre-dilatation and post-dilatation. Distal protection systems are furthermore limited by the
need to cross the lesion prior to deployment. Some studies have shown a relatively high
incidence of cerebral infarction even when distal protection devices are employed.

Cerebral protection with carotid flow reversal is a method that was developed as an
alternative to the use of distal protection devices. While novel in its approach, this
method too has its limitations. Another technique developed employs carotid flow reversal
prior to traversing the stenosis and can be accomplished by directly accessing the carotid
anatomy without the use of the transfemoral approach. Major benefits to this method include
a simpler route to the target lesion and the ability to perform the procedure on patients
with severe carotid tortuosity and difficult aortic arch anatomy.

Inclusion Criteria:

1. Patient must meet one of the following criteria regarding neurological symptom status
and degree of stenosis:

- Symptomatic: Stenosis must be greater than or equal to 50% as determined by
angiogram and the patient has a history of stroke (minor or non-disabling), TIA
and/or amaurosis fugax within 180 days of the procedure.

- Asymptomatic: Stenosis must be greater than or equal to 70% as determined by
angiogram without any neurological symptoms within the prior 180 days.

2. Target vessel must meet diameter requirements for stent (refer to selected stent IFU
for diameter requirements).

3. Patient has a discrete lesion located in the internal carotid artery (ICA) with or
without involvement of the contiguous common carotid artery (CCA).

4. Patient is >18 years of age.

5. Patient has no childbearing potential or has a negative pregnancy test within one
week prior to the study procedure.

6. Patient (or their legal guardian) understands the nature of the procedure and has
provided a signed informed consent using a form that has been reviewed and approved
by the Investigational Review Board/Ethics Committee of the respective clinical site
prior to the procedure. This will be obtained prior to participation in the study.

7. Patient is willing to comply with the protocol requirements and return to the
treatment center for all required clinical evaluations.

8. Patient meets at least one surgical high-risk criteria.

Exclusion Criteria:

1. Chronic atrial fibrillation, any episode of paroxysmal atrial fibrillation within the
past 6 months, or history of paroxysmal atrial fibrillation requiring chronic
anticoagulation.

2. Evolving stroke, severe dementia, intracranial tumor, history of spontaneous
intracranial hemorrhage within the past 12 months, recent stroke of sufficient size,
hemorrhagic transformation of an ischemic stroke within the past 60 days, history of
major stroke with major neurological deficit.

3. Active bleeding diathesis or coagulopathy or will refuse blood transfusion.

4. Had or will have CABG, endovascular stent procedure, valve intervention or vascular
surgery within 30 days before or after the intervention.

5. Recently (<60 days prior to procedure) implanted heart valve (either surgically or
endovascularly), which is a known source of emboli as confirmed on echocardiogram.

6. Recent GI bleed that would interfere with antiplatelet therapy.

7. Life expectance of < 12 months post procedure.

8. History of intolerance or allergic reaction to any of the study medications or stent
materials.

9. Myocardial Infarction within 72 hours prior to the intervention.

10. Has had neurologic illnesses within the past two years characterized by fleeting or
fixed neurologic deficit which cannot be distinguished from TIA or stroke.

11. Has Hgb <10 g/dl, platelet count <125,000/μl, uncorrected INR >1.5, bleeding time >1
minute beyond upper limit normal, or heparin-associated thrombocytopenia.

12. Occlusion or (TIMI 0) "string sign" >1cm of the ipsilateral common or internal
carotid artery.

13. Has vertebrobasilar insufficiency symptoms only, without clearly identifiable
symptoms referable to the study carotid artery.

14. Knowledge of cardiac sources of emboli, Ostium of Common Carotid Artery (CCA)
requires revascularization.

15. Presence of extensive or diffuse atherosclerotic disease involving the proximal
common carotid artery that would preclude the safe introduction of the study device.

16. Has less than 5cm between the clavicle and bifurcation.

17. Bilateral carotid stenosis if intervention is planned within the 30-day of the index
procedure.

18. An intraluminal filling defect that is not associated with an ulcerated target
lesion.

19. Abnormal angiographic findings.

20. Previous intervention in the ipsilateral proximal CCA or previous placed
intravascular stent in target vessel
We found this trial at
21
sites
2049 E 100th St
Cleveland, Ohio 44106
(216) 444-2200
Principal Investigator: Daniel Clair, MD
Phone: 216-444-0922
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
Principal Investigator: Christopher Kwolek, MD
Phone: 617-726-4957
?
mi
from
Boston, MA
Click here to add this to my saved trials
116th St and Broadway
New York, New York 10027
(212) 854-1754
Columbia University In 1897, the university moved from Forty-ninth Street and Madison Avenue, where it...
?
mi
from
New York, NY
Click here to add this to my saved trials
Albany, New York 12208
Principal Investigator: Manish Mehta, MD, MPH
Phone: 518-218-7107
?
mi
from
Albany, NY
Click here to add this to my saved trials
Ann Arbor, Michigan 48109
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Austin, Texas 78756
Principal Investigator: Mazin Foteh, MD
?
mi
from
Austin, TX
Click here to add this to my saved trials
4940 Eastern Ave
Baltimore, Maryland 21224
(410) 550-0100
Principal Investigator: Mahmoud Malas, MD
Phone: 410-550-1355
Johns Hopkins Bayview Medical Center There is no better story in American medicine in the...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Buffalo, New York 14209
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
Cleveland, Ohio 44106
Principal Investigator: Vikram Kashyap, MD
Phone: 216-983-4719
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
3535 Olentangy River Rd
Columbus, Ohio 43214
(614) 566-5000
Riverside Methodist Hospital Serving central Ohio since 1892, Riverside Methodist Hospital is consistently ranked one...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Dallas, Texas 75208
?
mi
from
Dallas, TX
Click here to add this to my saved trials
4500 S. Lancaster Rd.
Dallas, Texas 75216
800-849-3597
Dallas VA Medical Center VA North Texas Health Care System (VANTHCS) is a progressive health...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Flint, Michigan 48507
Principal Investigator: Robert Molnar, MD
Phone: 810-600-2009
?
mi
from
Flint, MI
Click here to add this to my saved trials
Greenville, South Carolina 29615
Principal Investigator: Tod Hanover, MD
Phone: 864-454-8288
?
mi
from
Greenville, SC
Click here to add this to my saved trials
Los Angeles, California 90095
Principal Investigator: Wes Moore, MD
Phone: 310-206-1115
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Norfolk, Virginia 23507
Principal Investigator: Rasesh M Shah, MD
Phone: 757-622-2649
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73120
Principal Investigator: Jim Melton, MD
Phone: 405-608-1294
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
601 E Rollins St
Orlando, Florida 32803
(407) 303-5600
Florida Hospital Florida Hospital is one of the country
?
mi
from
Orlando, FL
Click here to add this to my saved trials
St. Louis, Missouri 63108
Principal Investigator: Jeffery Jim, MD
Phone: 314-362-6257
?
mi
from
St. Louis, MO
Click here to add this to my saved trials
?
mi
from
Toledo,
Click here to add this to my saved trials
Toledo, Ohio 43606
?
mi
from
Toledo, OH
Click here to add this to my saved trials